BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454-464. [PMID: 22456601 DOI: 10.1038/ki.2012.63] [Cited by in Crossref: 328] [Cited by in F6Publishing: 285] [Article Influence: 32.8] [Reference Citation Analysis]
Number Citing Articles
1 Payette A, Patey N, Dragon-durey M, Frémeaux-bacchi V, Le Deist F, Lapeyraque A. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015;30:1033-7. [DOI: 10.1007/s00467-015-3061-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
2 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
3 Holle J, Berenberg-goßler L, Wu K, Beringer O, Kropp F, Müller D, Thumfart J. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol 2018;33:2289-98. [DOI: 10.1007/s00467-018-4034-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015;194:5129-38. [PMID: 25917093 DOI: 10.4049/jimmunol.1402770] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 9.4] [Reference Citation Analysis]
5 Gale DP, Maxwell PH. C3 glomerulonephritis and CFHR5 nephropathy. Nephrology Dialysis Transplantation 2013;28:282-8. [DOI: 10.1093/ndt/gfs441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
6 Hughley E, Nehus EJ, VandenHeuvel K, Augsburger BD, Jain NG, Lucky AW. Glomerulonephritis in Youth With Dystrophic Epidermolysis Bullosa. Kidney Int Rep 2021;6:538-43. [PMID: 33615081 DOI: 10.1016/j.ekir.2020.10.038] [Reference Citation Analysis]
7 Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125:2359-2369. [PMID: 25608561 DOI: 10.1182/blood-2014-10-609073] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 11.3] [Reference Citation Analysis]
8 Wada T, Nangaku M. Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int. 2013;84:441-450. [PMID: 23615508 DOI: 10.1038/ki.2013.134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bashir S, Hussain M, Afzal A, Hassan U, Hameed M, Mushtaq S. C4d at Crossroads Between Post-Infectious Glomerulonephritis and C3 Glomerulopathy. Int J Nephrol Renovasc Dis 2021;14:87-95. [PMID: 33732010 DOI: 10.2147/IJNRD.S285302] [Reference Citation Analysis]
11 Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol 2021. [PMID: 34002292 DOI: 10.1007/s00467-021-05088-7] [Reference Citation Analysis]
12 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Kumar A, Ramachandran R, Rawat A, Das R, Rayat CS, Kenwar DB, Sharma A, Gupta KL, Nada R. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy. Clin Kidney J 2021;14:291-300. [PMID: 33564431 DOI: 10.1093/ckj/sfz135] [Reference Citation Analysis]
14 Rusai K, Zaller V, Szilagyi A, Kain R, Prohaszka Z, Cook HT, Aufricht C, Arbeiter K. A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency. CEN Case Rep 2013;2:234-8. [PMID: 28509298 DOI: 10.1007/s13730-013-0070-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
15 Bagnasco SM. Beyond the microscope: interpreting renal biopsy findings in the era of precision medicine. Am J Physiol Renal Physiol 2018;315:F1652-5. [PMID: 30280602 DOI: 10.1152/ajprenal.00407.2018] [Reference Citation Analysis]
16 Appel GB. C3 Glomerulopathy: A New Disease Comes of Age. Mayo Clin Proc 2018;93:968-9. [PMID: 30077212 DOI: 10.1016/j.mayocp.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Blom AM, Corvillo F, Magda M, Stasiłojć G, Nozal P, Pérez-Valdivia MÁ, Cabello-Chaves V, Rodríguez de Córdoba S, López-Trascasa M, Okrój M. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. J Clin Immunol 2016;36:517-27. [PMID: 27146825 DOI: 10.1007/s10875-016-0290-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
18 Fakhouri F. [Clinical approach to primary membranoproliferative glomerulonephritis]. Nephrol Ther 2016;12 Suppl 1:S65-9. [PMID: 26972096 DOI: 10.1016/j.nephro.2016.01.008] [Reference Citation Analysis]
19 Cook HT. C3 glomerulopathy. F1000Res 2017;6:248. [PMID: 28357053 DOI: 10.12688/f1000research.10364.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
20 Tan M, Hao JB, Chu H, Wang FM, Song D, Zhu L, Yu F, Li YZ, Song Y, Zhao MH. Genetic variants in FH are associated with renal histopathologic subtypes of lupus nephritis: a large cohort study from China. Lupus 2017;26:1309-17. [PMID: 28403670 DOI: 10.1177/0961203317702254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yin G, Cheng Z, Zeng CH, Liu ZH. C3 glomerulonephritis in multiple myeloma: A case report and literature review. Medicine (Baltimore) 2016;95:e4843. [PMID: 27631242 DOI: 10.1097/MD.0000000000004843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Wilson V, Darlay R, Wong W, Wood KM, McFarlane J, Schejbel L, Schmidt IM, Harris CL, Tellez J, Hunze EM. Genotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomy. Am J Kidney Dis. 2013;62:978-983. [PMID: 23870792 DOI: 10.1053/j.ajkd.2013.05.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez Gómez V, Ávila AI, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Alonso Titos J, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M; Spanish Group for the Study of Glomerular Diseases GLOSEN. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol 2020;15:1287-98. [PMID: 32816888 DOI: 10.2215/CJN.15241219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Sansbury FH, Cordell HJ, Bingham C, Bromilow G, Nicholls A, Powell R, Shields B, Smyth L, Warwicker P, Strain L. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J Med Genet. 2014;51:756-764. [PMID: 25261570 DOI: 10.1136/jmedgenet-2014-102498] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
25 Sutherland LJ, Talreja H. C3-glomerulonephritis in New Zealand - a case series. BMC Nephrol 2020;21:399. [PMID: 32943008 DOI: 10.1186/s12882-020-02056-5] [Reference Citation Analysis]
26 Carr JM, Cabezas-Falcon S, Dubowsky JG, Hulme-Jones J, Gordon DL. Dengue virus and the complement alternative pathway. FEBS Lett 2020;594:2543-55. [PMID: 31943152 DOI: 10.1002/1873-3468.13730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Shin S, Seong Y, Lim BJ. Pathology of C3 Glomerulopathy. Child Kidney Dis 2019;23:93-9. [DOI: 10.3339/jkspn.2019.23.2.93] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wong EK, Anderson HE, Herbert AP, Challis RC, Brown P, Reis GS, Tellez JO, Strain L, Fluck N, Humphrey A, Macleod A, Richards A, Ahlert D, Santibanez-Koref M, Barlow PN, Marchbank KJ, Harris CL, Goodship TH, Kavanagh D. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014;25:2425-33. [PMID: 24722444 DOI: 10.1681/ASN.2013070732] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
29 Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. Clin Kidney J 2018;11:479-90. [PMID: 30094012 DOI: 10.1093/ckj/sfy006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8:634-642. [PMID: 23026947 DOI: 10.1038/nrneph.2012.213] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
31 Corvillo F, Okrój M, Nozal P, Melgosa M, Sánchez-Corral P, López-Trascasa M. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol 2019;10:886. [PMID: 31068950 DOI: 10.3389/fimmu.2019.00886] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
32 Kelleher C, Kocinsky H. Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease. Adv Chronic Kidney Dis 2020;27:95-103. [PMID: 32553251 DOI: 10.1053/j.ackd.2020.02.006] [Reference Citation Analysis]
33 Redahan L, Doyle R, O'Shaughnessy M, Dorman A, Little M, Conlon P. Familial MPGN - a case series: a clinical description of familial membranoproliferative glomerulonephritis amongst three Irish families. Ren Fail 2014;36:1333-6. [PMID: 24975727 DOI: 10.3109/0886022X.2014.931681] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Wallbach M, Gröne HJ, Kitze B, Müller GA, Koziolek MJ. Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy. American Journal of Kidney Diseases 2013;61:786-9. [DOI: 10.1053/j.ajkd.2012.11.049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
35 Janssen van Doorn K, Dirinck E, Verpooten GA, Couttenye MM. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J 2013;6:216-9. [PMID: 25006455 DOI: 10.1093/ckj/sfs190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
36 Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;95:281-95. [PMID: 30665569 DOI: 10.1016/j.kint.2018.11.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 31.5] [Reference Citation Analysis]
37 de Lorenzo A, Tallón S, Hernández-sevillano B, de Arriba G. C3 glomerulopathy: A new complement-based entity. Revista Clínica Española (English Edition) 2014;214:266-74. [DOI: 10.1016/j.rceng.2014.01.009] [Reference Citation Analysis]
38 Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89. [PMID: 24172683 DOI: 10.1038/ki.2013.377] [Cited by in Crossref: 356] [Cited by in F6Publishing: 297] [Article Influence: 39.6] [Reference Citation Analysis]
39 Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 2017;92:1232-41. [PMID: 28712854 DOI: 10.1016/j.kint.2017.04.017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
40 Nakano D, Nishiyama A. A novel role of renin inhibitor in the complement cascade. Kidney Int 2018;94:650-2. [PMID: 30243307 DOI: 10.1016/j.kint.2018.05.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
42 Silva F, Tavares J, Peixeiro RP, Oliveira J, Fernandes D, Castro A, Santos S, Coutinho R, Freitas C, Santos J, Pimentel JP, Coutinho J, Cabrita A. C3 glomerulopathy associated to B-cell chronic lymphocytic leukemia. Nefrología (English Edition) 2022;42:103-5. [DOI: 10.1016/j.nefroe.2020.08.007] [Reference Citation Analysis]
43 Turkmen K, Baloglu I, Ozer H. C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders. Int Urol Nephrol 2021. [PMID: 33389509 DOI: 10.1007/s11255-020-02729-y] [Reference Citation Analysis]
44 Michels MAHM, Volokhina EB, van de Kar NCAJ, van den Heuvel LPWJ. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy? Pediatr Nephrol 2019;34:1349-67. [PMID: 30141176 DOI: 10.1007/s00467-018-4042-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
45 Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik-Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Romana Rysava, Reiterova J, Saraga M, Tomáš Seeman, Zieg J, Sládková E, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Csuka D. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet J Rare Dis 2019;14:247. [PMID: 31703608 DOI: 10.1186/s13023-019-1237-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
46 Kumar A, Nada R, Ramachandran R, Rawat A, Tiewsoh K, Das R, Rayat CS, Gupta KL, Vasishta RK. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia. J Nephrol 2020;33:539-50. [PMID: 31820418 DOI: 10.1007/s40620-019-00672-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104:S11-S103. [PMID: 32301874 DOI: 10.1097/tp.0000000000003136] [Cited by in Crossref: 60] [Cited by in F6Publishing: 22] [Article Influence: 60.0] [Reference Citation Analysis]
48 Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019;15:129-43. [PMID: 30692664 DOI: 10.1038/s41581-018-0107-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
49 Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol 2017;13:359-67. [PMID: 28316335 DOI: 10.1038/nrneph.2017.37] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
50 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
51 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
52 Motwani SS, Herlitz L, Monga D, Jhaveri KD, Lam AQ; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol 2016;11:2260-72. [PMID: 27526706 DOI: 10.2215/CJN.02980316] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
53 Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22:231-237. [PMID: 23318699 DOI: 10.1097/mnh.0b013e32835da24c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
54 Han SS, Yu XJ, Wang SX, Zhou FD, Yu F, Zhao MH. A novel mutation in complement 2 accompanied by susceptibility variants in C3 glomerulonephritis: A case study. Nefrologia (Engl Ed) 2019;39:664-71. [PMID: 31014550 DOI: 10.1016/j.nefro.2019.01.008] [Reference Citation Analysis]
55 Ueda Y, Gullipalli D, Song WC. Modeling complement-driven diseases in transgenic mice: Values and limitations. Immunobiology 2016;221:1080-90. [PMID: 27371974 DOI: 10.1016/j.imbio.2016.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
56 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
57 Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Semin Immunol 2019;45:101331. [PMID: 31711769 DOI: 10.1016/j.smim.2019.101331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
58 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
59 Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93:977-85. [PMID: 29310824 DOI: 10.1016/j.kint.2017.10.022] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
60 Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol 2013;56:191-8. [PMID: 23816404 DOI: 10.1016/j.molimm.2013.06.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
61 Cook HT. Complement and kidney disease: . Current Opinion in Nephrology and Hypertension 2013;22:295-301. [DOI: 10.1097/mnh.0b013e32835ff9cb] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
62 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
63 Zhang X, Yu XJ, Li DY, Wang SX, Zhou FD, Zhao MH. C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China. Ren Fail 2021;43:1437-45. [PMID: 34658305 DOI: 10.1080/0886022X.2021.1990949] [Reference Citation Analysis]
64 Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 2017;129:1437-47. [PMID: 28069603 DOI: 10.1182/blood-2016-08-737163] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 13.4] [Reference Citation Analysis]
65 Legendre C, Sberro-Soussan R, Zuber J, Frémeaux-Bacchi V. The role of complement inhibition in kidney transplantation. Br Med Bull 2017;124:5-17. [PMID: 29069327 DOI: 10.1093/bmb/ldx037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wang X, Van Lookeren Campagne M, Katschke KJ Jr, Gullipalli D, Miwa T, Ueda Y, Wang Y, Palmer M, Xing G, Song WC. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. J Am Soc Nephrol 2018;29:2053-9. [PMID: 29895552 DOI: 10.1681/ASN.2018030270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
67 Łukawska E, Polcyn-adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med 2018;18:297-318. [DOI: 10.1007/s10238-018-0491-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
68 Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant 2021:gfab281. [PMID: 34596686 DOI: 10.1093/ndt/gfab281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
70 Mao S, Zhang J. Role of complement in glomerular diseases. Journal of Receptors and Signal Transduction 2015;36:319-25. [DOI: 10.3109/10799893.2015.1086882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Tesar V, Hruskova Z. Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach. Am J Nephrol 2017;46:93-5. [PMID: 28700984 DOI: 10.1159/000479014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, Frimat M, Ulinski T, Deschênes G, Burtey S, Delahousse M, Moulin B, Legendre C, Frémeaux-Bacchi V, Le Quintrec M. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. J Am Soc Nephrol 2017;28:1603-13. [PMID: 28096309 DOI: 10.1681/ASN.2016030343] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 10.2] [Reference Citation Analysis]
73 Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM. Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol 2016;196:1355-65. [PMID: 26729803 DOI: 10.4049/jimmunol.1500793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
74 Prakash R, Ali US, Ohri A, Parekhji SN, Deokar A, Khubchandani S. Clinico-pathological Profile and Outcome of C-3 Glomerulopathy in Indian Children. Indian J Nephrol 2020;30:370-6. [PMID: 33840955 DOI: 10.4103/ijn.IJN_226_18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest. 2014;124:145-155. [PMID: 24334459 DOI: 10.1172/jci71866] [Cited by in Crossref: 81] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
76 Lionaki S, Gakiopoulou H, Boletis JN. Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies. APMIS 2016;124:725-35. [PMID: 27356907 DOI: 10.1111/apm.12566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
77 Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-dahl T, Holt J, Christiansen D, Lau C, Brekke O, Armstrong E, Stefanovic V, Andersen JT, Sandlie I, Mollnes TE. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015;220:452-9. [DOI: 10.1016/j.imbio.2014.11.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
78 Bobart SA, Sethi S, Fervenza FC. C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome. Kidney Med 2019;1:36-9. [PMID: 32734182 DOI: 10.1016/j.xkme.2018.12.002] [Reference Citation Analysis]
79 Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Kidney Int 2017;91:1386-97. [PMID: 28139294 DOI: 10.1016/j.kint.2016.11.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
80 Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol. 2013;56:213-221. [PMID: 23790637 DOI: 10.1016/j.molimm.2013.05.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
81 Kaartinen K, Martola L, Räisänen-sokolowski A, Meri S. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment. Clinical Immunology 2018;187:104-6. [DOI: 10.1016/j.clim.2017.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology. 2015;220:993-998. [PMID: 25982307 DOI: 10.1016/j.imbio.2015.04.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
83 Borza DB. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. Matrix Biol. 2017;57-58:299-310. [PMID: 27609404 DOI: 10.1016/j.matbio.2016.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
84 Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc 2018;93:991-1008. [PMID: 30077216 DOI: 10.1016/j.mayocp.2018.05.019] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
85 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 2018;94:178-86. [PMID: 29729982 DOI: 10.1016/j.kint.2018.01.037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
87 Meyers KE, Liapis H, Atta MG. American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol 2014;9:818-28. [PMID: 24651072 DOI: 10.2215/CJN.12481213] [Reference Citation Analysis]
88 de Jong S, de Breuk A, Volokhina EB, Bakker B, Garanto A, Fauser S, Katti S, Hoyng CB, Lechanteur YTE, van den Heuvel LP, den Hollander AI. Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene. Hum Mol Genet 2021:ddab256. [PMID: 34508573 DOI: 10.1093/hmg/ddab256] [Reference Citation Analysis]
89 Nada R, Kumar A, Agrawal P, Ramachandran R, Sethi S. Renal and Pulmonary Dense Deposit Disease Presenting as Pulmonary-Renal Syndrome. Kidney Int Rep 2018;3:755-61. [PMID: 29854987 DOI: 10.1016/j.ekir.2018.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
90 Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol 2016;12:217-31. [PMID: 26949177 DOI: 10.1038/nrneph.2016.18] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
91 Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci 2020;21:E525. [PMID: 31947692 DOI: 10.3390/ijms21020525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
92 Chae DW. New classification of membranoproliferative glomerulonephritis: a good start but a long way to go. Kidney Res Clin Pract 2014;33:171-3. [PMID: 26885472 DOI: 10.1016/j.krcp.2014.10.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Zhao W, Ding Y, Lu J, Zhang T, Chen D, Zhang H, Zeng C, Liu Z, Chen H. Genetic analysis of the complement pathway in C3 glomerulopathy. Nephrol Dial Transplant 2018;33:1919-27. [PMID: 29566171 DOI: 10.1093/ndt/gfy033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
94 Mella A, Messina M, Lavacca A, Biancone L. Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant 2014; 4(3): 168-175 [PMID: 25346889 DOI: 10.5500/wjt.v4.i3.168] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
95 Puri P, Walters GD, Fadia MN, Konia M, Gibson KA, Jiang SH. The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis. BMC Nephrol 2020;21:265. [PMID: 32652953 DOI: 10.1186/s12882-020-01923-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Riedl M, Thorner P, Licht C. C3 Glomerulopathy. Pediatr Nephrol 2017;32:43-57. [PMID: 27056062 DOI: 10.1007/s00467-015-3310-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
97 Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
98 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Bomback AS. Anti-complement therapy for glomerular diseases. Adv Chronic Kidney Dis. 2014;21:152-158. [PMID: 24602464 DOI: 10.1053/j.ackd.2013.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
100 Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol 2017;38:383-94. [PMID: 28416449 DOI: 10.1016/j.it.2017.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
101 Santoro D, Siligato R, Vadalà C, Lucanto M, Cristadoro S, Conti G, Buemi M, Costa S, Sabadini E, Magazzù G. C3 glomerulopathy in cystic fibrosis: a case report. BMC Nephrol 2018;19:73. [PMID: 29592796 DOI: 10.1186/s12882-018-0880-y] [Reference Citation Analysis]
102 Larsen CP, Ambuzs JM, Bonsib SM, Boils CL, Cossey LN, Messias NC, Silva FG, Wang YH, Gokden N, Walker PD. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int. 2014;86:154-161. [PMID: 24429395 DOI: 10.1038/ki.2013.548] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
103 Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018;19:7. [PMID: 29329521 DOI: 10.1186/s12882-017-0802-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
104 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
105 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175-87. [DOI: 10.1016/j.molimm.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Medjeral-Thomas NR, Pickering MC, Cook HT. Complement and kidney disease, new insights. Curr Opin Nephrol Hypertens 2021;30:310-6. [PMID: 33767058 DOI: 10.1097/MNH.0000000000000705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018;200:2464-78. [PMID: 29500241 DOI: 10.4049/jimmunol.1701695] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
108 Le Clech A, Simon-tillaux N, Provôt F, Delmas Y, Vieira-martins P, Limou S, Halimi J, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-chiche N, Rondeau E, Frémeaux-bacchi V, Fakhouri F. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International 2019;95:1443-52. [DOI: 10.1016/j.kint.2019.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
109 Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU, Temurhan S, Oztop N, Kilicaslan I, Sever MS. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? Am J Nephrol 2017;46:96-107. [DOI: 10.1159/000479012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
110 Takehara E, Mandai S, Shikuma S, Akita W, Chiga M, Mori T, Oda T, Kuwahara M, Uchida S. Post-infectious Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Deposits Associated with Complement Factor H Mutation. Intern Med 2017;56:811-7. [PMID: 28381748 DOI: 10.2169/internalmedicine.56.7778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
111 Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I, Sugiyama H, Fujimoto S, Miura K, Matsumura C, Gotoh Y, Suzuki H, Kuroki A, Yoshino A, Nakatani S, Hiromura K, Yamamoto R, Yokoyama H, Narita I, Isaka Y. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One 2021;16:e0257397. [PMID: 34520493 DOI: 10.1371/journal.pone.0257397] [Reference Citation Analysis]
112 Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, Pérez de José A, López I, Fernández L, Pérez Gómez V, Ávila A, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, Goicoechea de Jorge E, Caravaca F, Praga M; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Validation of a Histologic Scoring Index for C3 Glomerulopathy. Am J Kidney Dis 2021;77:684-695.e1. [PMID: 33359150 DOI: 10.1053/j.ajkd.2020.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
114 Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis 2018;72:84-92. [PMID: 29429752 DOI: 10.1053/j.ajkd.2017.11.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
115 Koenderman L, Buurman W, Daha MR. The innate immune response. Immunol Lett 2014;162:95-102. [PMID: 25455595 DOI: 10.1016/j.imlet.2014.10.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
116 Wong L, Moran S, Lavin PJ, Dorman AM, Conlon PJ. Kidney transplant outcomes in familial C3 glomerulopathy. Clin Kidney J. 2016;9:403-407. [PMID: 27274824 DOI: 10.1093/ckj/sfw020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
117 Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? World J Transplant 2017; 7(6): 285-300 [PMID: 29312858 DOI: 10.5500/wjt.v7.i6.285] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
118 Gambella A, Barreca A, Biancone L, Roccatello D, Peruzzi L, Besso L, Licata C, Attanasio A, Papotti M, Cassoni P. Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. Biomolecules 2022;12:298. [DOI: 10.3390/biom12020298] [Reference Citation Analysis]
119 Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, Delmas Y, Le Quintrec M, Guerrot D, Jourde-Chiche N, Ribes D, Ronco P, Bridoux F, Fremeaux-Bacchi V. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Front Immunol 2018;9:2260. [PMID: 30333829 DOI: 10.3389/fimmu.2018.02260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
120 Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 2015;35:199-205. [PMID: 25663093 DOI: 10.1007/s10875-015-0137-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
121 Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci 2019;20:E6336. [PMID: 31888179 DOI: 10.3390/ijms20246336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
122 Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Applying complement therapeutics to rare diseases. Clin Immunol 2015;161:225-40. [PMID: 26341313 DOI: 10.1016/j.clim.2015.08.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
123 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
124 Caliskan Y, Kiryluk K. Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis 2014;21:205-16. [PMID: 24602470 DOI: 10.1053/j.ackd.2013.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
125 Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 2016;221:1046-57. [PMID: 27353192 DOI: 10.1016/j.imbio.2016.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
126 Wen J, Wang W, Xu F, Sun J, Chen J, Ni X. C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report. BMC Nephrol 2018;19:148. [PMID: 29940891 DOI: 10.1186/s12882-018-0952-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Garam N, Cserhalmi M, Prohászka Z, Szilágyi Á, Veszeli N, Szabó E, Uzonyi B, Iliás A, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Stajic N, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Józsi M, Csuka D. FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Front Immunol 2021;12:720183. [PMID: 34566977 DOI: 10.3389/fimmu.2021.720183] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Geerlings MJ, Volokhina EB, de Jong EK, van de Kar N, Pauper M, Hoyng CB, van den Heuvel LP, den Hollander AI. Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration. Clin Genet 2018;94:330-8. [PMID: 29888403 DOI: 10.1111/cge.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
129 Häffner K, Michelfelder S, Pohl M. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol 2015;30:1951-9. [DOI: 10.1007/s00467-015-3111-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
130 Chauvet S, Roumenina LT, Bruneau S, Marinozzi MC, Rybkine T, Schramm EC, Java A, Atkinson JP, Aldigier JC, Bridoux F, Touchard G, Fremeaux-Bacchi V. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol 2016;27:1665-77. [PMID: 26471127 DOI: 10.1681/ASN.2015040348] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
131 Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62:403-41. [PMID: 23871408 DOI: 10.1053/j.ajkd.2013.06.002] [Cited by in Crossref: 134] [Cited by in F6Publishing: 104] [Article Influence: 14.9] [Reference Citation Analysis]
132 Asano M, Oda T, Mizuno M. A case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection. CEN Case Rep 2021. [PMID: 34799818 DOI: 10.1007/s13730-021-00662-2] [Reference Citation Analysis]
133 Timmermans SA, van Paassen P, Cohen Tervaert JW. Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications. Expert Rev Clin Immunol 2015;11:489-500. [PMID: 25754988 DOI: 10.1586/1744666X.2015.1024659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). Eur J Pediatr 2014;173:767-72. [PMID: 24384791 DOI: 10.1007/s00431-013-2245-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
135 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
136 Nester CM, Smith RJ. Complement inhibition in C3 glomerulopathy. Semin Immunol 2016;28:241-9. [PMID: 27402056 DOI: 10.1016/j.smim.2016.06.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
137 Angeletti A, Reyes-Bahamonde J, Cravedi P, Campbell KN. Complement in Non-Antibody-Mediated Kidney Diseases. Front Med (Lausanne) 2017;4:99. [PMID: 28748184 DOI: 10.3389/fmed.2017.00099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
138 Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol 2016;11:1856-66. [PMID: 27340286 DOI: 10.2215/CJN.01710216] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
139 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
140 Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;65:484-489. [PMID: 25530108 DOI: 10.1053/j.ajkd.2014.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
141 Kobbe R, Schild R, Christner M, Oh J, Loos S, Kemper MJ. Case report - atypical hemolytic uremic syndrome triggered by influenza B. BMC Nephrol 2017;18:96. [PMID: 28320387 DOI: 10.1186/s12882-017-0512-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
142 Infante B, Rossini M, Leo S, Troise D, Netti GS, Ranieri E, Gesualdo L, Castellano G, Stallone G. Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem. Int J Mol Sci 2020;21:E5954. [PMID: 32824988 DOI: 10.3390/ijms21175954] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 2016;90:109-122. [PMID: 27165610 DOI: 10.1016/j.kint.2016.02.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
144 Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219 [PMID: 30370231 DOI: 10.5500/wjt.v8.i6.203] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
145 Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant. 2013;28:1685-1693. [PMID: 23479095 DOI: 10.1093/ndt/gfs430] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
146 Badiola J, Navarrete-Navarrete N, Sabio JM. Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatol Int 2019;39:359-65. [PMID: 30554307 DOI: 10.1007/s00296-018-4228-5] [Reference Citation Analysis]
147 Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis 2020;27:104-10. [PMID: 32553242 DOI: 10.1053/j.ackd.2019.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
148 Trutin I, Oletić L, Galešić Ljubanović D, Turudić D, Milošević D. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY. Acta Clin Croat 2021;60:141-5. [PMID: 34588735 DOI: 10.20471/acc.2021.60.01.21] [Reference Citation Analysis]
149 Nozal P, López-Trascasa M. Autoantibodies against alternative complement pathway proteins in renal pathologies. Nefrologia 2016;36:489-95. [PMID: 27267919 DOI: 10.1016/j.nefro.2016.01.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
150 Gao S, Song H. Integrated comparison of the mRNAome in cartilage, synovium, and macrophages in osteoarthritis. Z Rheumatol 2022. [PMID: 35178608 DOI: 10.1007/s00393-022-01171-y] [Reference Citation Analysis]
151 Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem. 2016;291:8214-8230. [PMID: 26903516 DOI: 10.1074/jbc.m115.693119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
152 Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
153 Defendi F, Thielens NM, Clavarino G, Cesbron JY, Dumestre-Pérard C. The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease. Clin Rev Allergy Immunol 2020;58:229-51. [PMID: 31834594 DOI: 10.1007/s12016-019-08774-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
154 Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation 2013;28:2246-59. [DOI: 10.1093/ndt/gft220] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
155 Veríssimo R, Mateus C, Laranjinha I, Manso RT, Dickson J, Gonçalves M, Gaspar MA, Machado D. Thrombotic microangiopathy triggered by podocytopathy. Clin Nephrol Case Stud 2021;9:110-6. [PMID: 34646728 DOI: 10.5414/CNCS110534] [Reference Citation Analysis]
156 Noris M, Remuzzi G. Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology 2017;37:447-63. [DOI: 10.1016/j.semnephrol.2017.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
157 Michels MAHM, van de Kar NCAJ, Volokhina EB, van den Heuvel BPWJ. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity. In: Roumenina LT, editor. The Complement System. New York: Springer US; 2021. pp. 83-96. [DOI: 10.1007/978-1-0716-1016-9_8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Barbour TD, Pickering MC, Terence Cook H. Dense deposit disease and C3 glomerulopathy. Semin Nephrol 2013;33:493-507. [PMID: 24161036 DOI: 10.1016/j.semnephrol.2013.08.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
159 Angeletti A, Cantarelli C, Petrosyan A, Andrighetto S, Budge K, D'Agati VD, Hartzell S, Malvi D, Donadei C, Thurman JM, Galešić-Ljubanović D, He JC, Xiao W, Campbell KN, Wong J, Fischman C, Manrique J, Zaza G, Fiaccadori E, La Manna G, Fribourg M, Leventhal J, Da Sacco S, Perin L, Heeger PS, Cravedi P. Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. J Exp Med 2020;217:e20191699. [PMID: 32717081 DOI: 10.1084/jem.20191699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
160 Chabannes M, Frémeaux-bacchi V, Chauvet S. Detection of C3 Nephritic Factor by Hemolytic Assay. In: Roumenina LT, editor. The Complement System. New York: Springer US; 2021. pp. 147-58. [DOI: 10.1007/978-1-0716-1016-9_15] [Reference Citation Analysis]
161 Hawfield A, Iskandar SS, Smith RJ. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy. Am J Kidney Dis 2013;61:828-31. [PMID: 23391537 DOI: 10.1053/j.ajkd.2012.11.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
162 Al-Ghaithi B, Chanchlani R, Riedl M, Thorner P, Licht C. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatr Nephrol 2016;31:2079-86. [PMID: 27008643 DOI: 10.1007/s00467-015-3311-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
163 Michels MAHM, van de Kar NCAJ, van den Bos RM, van der Velden TJAM, van Kraaij SAW, Sarlea SA, Gracchi V, Oosterveld MJS, Volokhina EB, van den Heuvel LPWJ. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Front Immunol 2019;10:1350. [PMID: 31263464 DOI: 10.3389/fimmu.2019.01350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
164 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
165 Roumenina LT, Zuber J, Frémeaux-Bacchi V. Physiological and therapeutic complement regulators in kidney transplantation. Curr Opin Organ Transplant 2013;18:421-9. [PMID: 23838647 DOI: 10.1097/MOT.0b013e32836370ce] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
166 Bu F, Borsa N, Gianluigi A, Smith RJ. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol 2012;2012:370426. [PMID: 23251215 DOI: 10.1155/2012/370426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
167 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
168 Grunenwald A, Roumenina LT. The Benefits of Complement Measurements for the Clinical Practice. Methods Mol Biol 2021;2227:1-20. [PMID: 33847926 DOI: 10.1007/978-1-0716-1016-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Crit Rev Oncol Hematol 2020;149:102926. [PMID: 32199132 DOI: 10.1016/j.critrevonc.2020.102926] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, Shao D, Akber A, Fremeaux-Bacchi V, Sethi S, Nester CM, Smith RJH. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. Am J Kidney Dis 2017;70:834-43. [PMID: 28838767 DOI: 10.1053/j.ajkd.2017.07.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
171 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Ann Hematol 2020;99:703-14. [PMID: 32103323 DOI: 10.1007/s00277-020-03971-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Yu Y, Triebwasser MP, Wong EK, Schramm EC, Thomas B, Reynolds R, Mardis ER, Atkinson JP, Daly M, Raychaudhuri S, Kavanagh D, Seddon JM. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet 2014;23:5283-93. [PMID: 24847005 DOI: 10.1093/hmg/ddu226] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
173 Ding Y, Zhao W, Zhang T, Qiang H, Lu J, Su X, Wen S, Xu F, Zhang M, Zhang H, Zeng C, Liu Z, Chen H. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies. Sci Rep 2017;7:6004. [PMID: 28729648 DOI: 10.1038/s41598-017-05173-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
174 Bernuy-Guevara C, Chehade H, Muller YD, Vionnet J, Cachat F, Guzzo G, Ochoa-Sangrador C, Álvarez FJ, Teta D, Martín-García D, Adler M, de Paz FJ, Lizaraso-Soto F, Pascual M, Herrera-Gómez F. The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines 2020;8:E355. [PMID: 32948059 DOI: 10.3390/biomedicines8090355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
175 Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, Sakhuja V, Joshi K. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience. Diagn Pathol 2015;10:6. [PMID: 25889427 DOI: 10.1186/s13000-015-0233-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
176 Zewde N, Morikis D. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. PLoS One 2018;13:e0198644. [PMID: 29874282 DOI: 10.1371/journal.pone.0198644] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
177 Bharati J, Tiewsoh K, Kumar A, Nada R, Rathi M, Gupta KL, Kohli HS, Jha V, Ramachandran R. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy. Clin Kidney J 2019;12:483-7. [PMID: 31384438 DOI: 10.1093/ckj/sfy127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
178 De Souza L, Prunster J, Chan D, Chakera A, Lim WH. Recurrent glomerulonephritis after kidney transplantation: a practical approach. Curr Opin Organ Transplant 2021;26:360-80. [PMID: 34039882 DOI: 10.1097/MOT.0000000000000887] [Reference Citation Analysis]
179 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
180 Kaynar K, Güvercin B, Safarlı S, Mungan S, Şahin M. C3 glomerulonephritis accompanied with lupus nephritis. Nefrología (English Edition) 2021;41:595-7. [DOI: 10.1016/j.nefroe.2021.11.006] [Reference Citation Analysis]
181 Fervenza FC, Sethi S. Circulating complement levels and C3 glomerulopathy. Clin J Am Soc Nephrol 2014;9:1829-31. [PMID: 25341723 DOI: 10.2215/CJN.09620914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
182 Lloyd IE, Gallan A, Huston HK, Raphael KL, Miller DV, Revelo MP, Khalighi MA. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin Kidney J 2016;9:794-9. [PMID: 27994856 DOI: 10.1093/ckj/sfw090] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
183 Nakano M, Karasawa K, Moriyama T, Uchida K, Nitta K. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol 2019;23:852-8. [PMID: 30854618 DOI: 10.1007/s10157-019-01716-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik-Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Csuka D. Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. Clin Kidney J 2020;13:225-34. [PMID: 32296528 DOI: 10.1093/ckj/sfz073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015;11:14-22. [PMID: 25447133 DOI: 10.1038/nrneph.2014.217] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
186 Wong EKS, Marchbank KJ, Lomax-Browne H, Pappworth IY, Denton H, Cooke K, Ward S, McLoughlin AC, Richardson G, Wilson V, Harris CL, Morgan BP, Hakobyan S, McAlinden P, Gale DP, Maxwell H, Christian M, Malcomson R, Goodship THJ, Marks SD, Pickering MC, Kavanagh D, Cook HT, Johnson SA; MPGN/DDD/C3 Glomerulopathy Rare Disease Group and National Study of MPGN/DDD/C3 Glomerulopathy Investigators. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. Clin J Am Soc Nephrol 2021;16:1639-51. [PMID: 34551983 DOI: 10.2215/CJN.00320121] [Reference Citation Analysis]
187 Chauvet S, Berthaud R, Devriese M, Mignotet M, Vieira Martins P, Robe-Rybkine T, Miteva MA, Gyulkhandanyan A, Ryckewaert A, Louillet F, Merieau E, Mestrallet G, Rousset-Rouvière C, Thervet E, Hogan J, Ulinski T, Villoutreix BO, Roumenina L, Boyer O, Frémeaux-Bacchi V. Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 2020;31:829-40. [PMID: 32034108 DOI: 10.1681/ASN.2019080851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
188 Hosoya M, Kawasaki Y, Maeda R, Sato M, Suyama K, Hashimoto K, Hosoya M. Predictive factors for poor outcome in pediatric C3 glomerulonephritis. Fukushima J Med Sci 2018;64:142-50. [PMID: 30369521 DOI: 10.5387/fms.2018-05] [Reference Citation Analysis]
189 Kaynar K, Güvercin B, Safarlı S, Mungan S, Şahin M. C3 glomerulonephritis accompanied with lupus nephritis. Nefrologia (Engl Ed) 2021:S0211-6995(20)30185-5. [PMID: 33413802 DOI: 10.1016/j.nefro.2020.09.006] [Reference Citation Analysis]
190 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Nicolas C, Vuiblet V, Baudouin V, Macher M, Vrillon I, Biebuyck-gouge N, Dehennault M, Gié S, Morin D, Nivet H, Nobili F, Ulinski T, Ranchin B, Marinozzi MC, Ngo S, Frémeaux-bacchi V, Pietrement C. C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol 2014;29:85-94. [DOI: 10.1007/s00467-013-2605-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
192 Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 2021. [PMID: 34476601 DOI: 10.1007/s00467-021-05221-6] [Reference Citation Analysis]
193 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
194 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
195 Sofat R, Mangione PP, Gallimore JR, Hakobyan S, Hughes TR, Shah T, Goodship T, D'Aiuto F, Langenberg C, Wareham N, Morgan BP, Pepys MB, Hingorani AD. Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. J Immunol Methods 2013;390:63-73. [PMID: 23376722 DOI: 10.1016/j.jim.2013.01.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
196 Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol. 2016;11:94. [PMID: 27717365 DOI: 10.1186/s13000-016-0547-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
197 Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy., Nastasi. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018;29:283-94. [PMID: 29030465 DOI: 10.1681/ASN.2017030258] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 7.6] [Reference Citation Analysis]
198 Gupta N, Wakefield DN, Clapp WL, Garin EH. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia 2017;37:78-86. [PMID: 27595516 DOI: 10.1016/j.nefro.2016.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
199 Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M, Suyama K, Hashimoto K, Hosoya M. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol 2016;31:1091-9. [DOI: 10.1007/s00467-015-3307-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
200 Haas M. Emerging Concepts and Controversies in Renal Pathology. Surgical Pathology Clinics 2014;7:457-67. [DOI: 10.1016/j.path.2014.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Wong EKS, Hallam TM, Brocklebank V, Walsh PR, Smith-Jackson K, Shuttleworth VG, Cox TE, Anderson HE, Barlow PN, Marchbank KJ, Harris CL, Kavanagh D. Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD. Front Immunol 2020;11:602284. [PMID: 33519811 DOI: 10.3389/fimmu.2020.602284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 2016;221:1247-58. [PMID: 27475991 DOI: 10.1016/j.imbio.2016.06.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
203 Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS. Diagnosis of complement alternative pathway disorders. Kidney International 2016;89:278-88. [DOI: 10.1016/j.kint.2015.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
204 Zahir Z, Wani AS, Gupta A, Agrawal V. Pediatric C3 glomerulopathy: a 12-year single-center experience. Pediatr Nephrol 2021;36:601-10. [PMID: 33000324 DOI: 10.1007/s00467-020-04768-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Bullen A, Shah MM. De Novo Postinfectious Glomerulonephritis Secondary to Nephritogenic Streptococci as the Cause of Transplant Acute Kidney Injury: A Case Report and Review of the Literature. Case Rep Transplant 2018;2018:2695178. [PMID: 29955411 DOI: 10.1155/2018/2695178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Hirashio S, Satoh A, Arima T, Mandai K, Awaya T, Oshima K, Hara S, Masaki T. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report. BMC Nephrol 2018;19:108. [PMID: 29724182 DOI: 10.1186/s12882-018-0905-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
207 Master Sankar Raj V, Gordillo R, Chand DH. Overview of C3 Glomerulopathy. Front Pediatr 2016;4:45. [PMID: 27200326 DOI: 10.3389/fped.2016.00045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479-492. [PMID: 24161035 DOI: 10.1016/j.semnephrol.2013.08.001] [Cited by in Crossref: 350] [Cited by in F6Publishing: 309] [Article Influence: 43.8] [Reference Citation Analysis]
209 Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney Int Rep 2020;5:2313-24. [PMID: 33305125 DOI: 10.1016/j.ekir.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
210 Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr. 2013;25:225-231. [PMID: 23486421 DOI: 10.1097/mop.0b013e32835df4a3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
211 Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 2017;92:876-87. [PMID: 28729035 DOI: 10.1016/j.kint.2017.04.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
212 Hakroush S, Gersmann AK, Tampe B. Histopathological and ultrastructural monitoring of remission induction in crescentic C3 glomerulonephritis. J Nephrol 2021. [PMID: 34741759 DOI: 10.1007/s40620-021-01169-w] [Reference Citation Analysis]
213 Xiao X, Ghossein C, Tortajada A, Zhang Y, Meyer N, Jones M, Borsa NG, Nester CM, Thomas CP, de Córdoba SR, Smith RJ. Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene. Mol Immunol 2016;77:89-96. [PMID: 27490940 DOI: 10.1016/j.molimm.2016.07.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
214 Sánchez-Corral P, Pouw RB, López-Trascasa M, Józsi M. Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family. Front Immunol 2018;9:1607. [PMID: 30050540 DOI: 10.3389/fimmu.2018.01607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
215 Farris AB, Vizcarra J, Amgad M, Cooper LAD, Gutman D, Hogan J. Artificial intelligence and algorithmic computational pathology: an introduction with renal allograft examples. Histopathology 2021;78:791-804. [PMID: 33211332 DOI: 10.1111/his.14304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
216 Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology 2016;71:131-42. [DOI: 10.1016/j.molimm.2016.01.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
217 Abdul-Aziz R, Deng R, Liu L, Tarsi S, Waz WR, Wu X. Complete Renal Recovery in Pediatric Patient with C3 Glomerulonephritis: A Case Report. Case Rep Nephrol Dial 2021;11:261-9. [PMID: 34703825 DOI: 10.1159/000518714] [Reference Citation Analysis]
218 Józsi M, Reuter S, Nozal P, López-trascasa M, Sánchez-corral P, Prohászka Z, Uzonyi B. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunology Letters 2014;160:163-71. [DOI: 10.1016/j.imlet.2014.01.014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
219 Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS. Kidney Transplantation in C3 Glomerulopathy: A Case Series. Am J Kidney Dis 2019;73:316-23. [PMID: 30413277 DOI: 10.1053/j.ajkd.2018.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
220 Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol 2016;31:683-7. [DOI: 10.1007/s00467-015-3306-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
221 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
222 Taylor RL, Poulter JA, Downes SM, McKibbin M, Khan KN, Inglehearn CF, Webster AR, Hardcastle AJ, Michaelides M, Bishop PN, Clark SJ, Black GC; United Kingdom Inherited Retinal Dystrophy Consortium. Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular Drusen. Ophthalmology 2019;126:1410-21. [PMID: 30905644 DOI: 10.1016/j.ophtha.2019.03.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
223 Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016;90:746-752. [PMID: 27325183 DOI: 10.1016/j.kint.2016.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
224 Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-11. [PMID: 24408225 DOI: 10.1007/s00467-013-2711-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
225 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
226 Thomas S, Ranganathan D, Francis L, Madhan K, John GT. Current concepts in C3 glomerulopathy. Indian J Nephrol. 2014;24:339-348. [PMID: 25484526 DOI: 10.4103/0971-4065.134089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
227 Alexander MP, Fervenza FC, De Vriese AS, Smith RJH, Nasr SH, Cornell LD, Herrera Hernandez LP, Zhang Y, Sethi S. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? J Nephrol 2016;29:203-9. [DOI: 10.1007/s40620-015-0218-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
228 Ramadass M, Ghebrehiwet B, Smith RJ, Kew RR. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol 2014;192:1220-30. [PMID: 24367026 DOI: 10.4049/jimmunol.1302288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
229 Cook HT, Pickering MC. Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury. J Am Soc Nephrol 2018;29:9-12. [PMID: 29229764 DOI: 10.1681/ASN.2017111183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
230 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
231 Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013;191:912-21. [PMID: 23772024 DOI: 10.4049/jimmunol.1300269] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
232 Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey MA, Fremeaux-Bacchi V, Roumenina LT. Autoantibodies Against C3b-Functional Consequences and Disease Relevance. Front Immunol 2019;10:64. [PMID: 30761135 DOI: 10.3389/fimmu.2019.00064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
233 Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 2017;21:541-51. [PMID: 27878657 DOI: 10.1007/s10157-016-1358-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
234 Chen SF, Wang FM, Li ZY, Yu F, Chen M, Zhao MH. The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis. Clin Immunol 2017;175:41-50. [PMID: 27939215 DOI: 10.1016/j.clim.2016.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
235 Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol 2019;34:1311-23. [PMID: 29948306 DOI: 10.1007/s00467-018-3989-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
236 Barbour S, Gill JS. Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. Am J Transplant. 2015;15:312-319. [PMID: 25612487 DOI: 10.1111/ajt.13042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
237 Alfandary H, Davidovits M. Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I. Pediatr Nephrol 2015;30:2129-34. [DOI: 10.1007/s00467-015-3166-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
238 Salvadori M, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. World J Transplant 2016; 6(4): 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
239 Brilland B, Garnier A, Chevailler A, Jeannin P, Subra J, Augusto J. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmunity Reviews 2020;19:102424. [DOI: 10.1016/j.autrev.2019.102424] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
240 Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: Frequency, clinical features, and outcome in children: MPGN and C3 glomerulonephritis in children. Nephrology 2015;20:286-92. [DOI: 10.1111/nep.12382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
241 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
242 Vasilev VV, Noe R, Dragon-Durey MA, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT. Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. J Biol Chem 2015;290:25343-55. [PMID: 26245903 DOI: 10.1074/jbc.M115.647008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
243 Perkins SJ. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Adv Chronic Kidney Dis 2020;27:120-127.e4. [PMID: 32553244 DOI: 10.1053/j.ackd.2020.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
244 Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol. 2013;56:170-180. [PMID: 23830046 DOI: 10.1016/j.molimm.2013.06.001] [Cited by in Crossref: 145] [Cited by in F6Publishing: 130] [Article Influence: 16.1] [Reference Citation Analysis]
245 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
246 Fakhouri F, Le Quintrec M, Frémeaux-Bacchi V. Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int 2020;98:1135-48. [PMID: 32622830 DOI: 10.1016/j.kint.2020.05.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
247 Chen SF, Chen M. Complement Activation in Progression of Chronic Kidney Disease. Adv Exp Med Biol 2019;1165:423-41. [PMID: 31399977 DOI: 10.1007/978-981-13-8871-2_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
248 Drake KA, Ellington N, Gattineni J, Torrealba JR, Hendricks AR. Clinicopathological features of C3 glomerulopathy in children: a single-center experience. Pediatr Nephrol 2020;35:153-62. [PMID: 31667615 DOI: 10.1007/s00467-019-04388-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol. 2013;28:2227-2231. [PMID: 23892798 DOI: 10.1007/s00467-013-2565-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
250 Singh G, Singh SK, Nalwa A, Singh L, Pradeep I, Barwad A, Sinha A, Hari P, Bagga A, Bagchi S, Agarwal SK, Dinda AK. Glomerular C4d Staining Does Not Exclude a C3 Glomerulopathy. Kidney Int Rep 2019;4:698-709. [PMID: 31080925 DOI: 10.1016/j.ekir.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
251 Holle J, Habbig S, Gratopp A, Mauritsch A, Müller D, Thumfart J. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol 2021;36:1311-5. [PMID: 33538911 DOI: 10.1007/s00467-021-04952-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
252 Nahm JH, Song SH, Kim YS, Cheong HI, Lim BJ, Kim BS, Jeong HJ. De novo C3 glomerulonephritis in a renal allograft. Ultrastruct Pathol. 2016;40:112-115. [PMID: 26986539 DOI: 10.3109/01913123.2016.1154634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
253 Ding Y, Tang X, Du Y, Chen H, Yu D, Zhu B, Yuan B. Co-existence of Alport syndrome and C3 glomerulonephritis in a proband with family history. Eur J Med Res 2021;26:71. [PMID: 34238373 DOI: 10.1186/s40001-021-00543-5] [Reference Citation Analysis]
254 Michels MAHM, van de Kar NCAJ, van Kraaij SAW, Sarlea SA, Gracchi V, Engels FAPT, Dorresteijn EM, van der Deure J, Duineveld C, Wetzels JFM, van den Heuvel LPWJ, Volokhina EB. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Immunol 2021;12:715704. [PMID: 34456924 DOI: 10.3389/fimmu.2021.715704] [Reference Citation Analysis]
255 Lee H, Wang L, Ni FF, Yang XY, Feng SP, Gao XJ, Chi H, Luo YT, Chen XL, Yang BH, Wan JL, Jiao J, Wu DQ, Zhang GF, Wang M, Yang HP, Chan H, Li Q. Association between HLA alleles and sub-phenotype of childhood steroid-sensitive nephrotic syndrome. World J Pediatr 2022. [PMID: 34973118 DOI: 10.1007/s12519-021-00489-y] [Reference Citation Analysis]
256 Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Front Immunol 2018;9:2329. [PMID: 30487789 DOI: 10.3389/fimmu.2018.02329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
257 Savige J, Amos L, Ierino F, Mack HG, Symons RC, Hughes P, Nicholls K, Colville D. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet 2016;37:369-76. [PMID: 26915021 DOI: 10.3109/13816810.2015.1101777] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
258 Felberg A, Urban A, Borowska A, Stasiłojć G, Taszner M, Hellmann A, Blom AM, Okrój M. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics. Cancer Immunol Immunother 2019;68:587-98. [PMID: 30725204 DOI: 10.1007/s00262-019-02304-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
259 Li LL, Li ZY, Wang SX, Yu XJ, Tan Y, Wang Y, Yu F, Zhao MH. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis. BMC Nephrol 2019;20:459. [PMID: 31823738 DOI: 10.1186/s12882-019-1640-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
260 Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53. [PMID: 24178974 DOI: 10.2215/CJN.04700513] [Cited by in Crossref: 121] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
261 Michels MAHM, van de Kar NCAJ, Okrój M, Blom AM, van Kraaij SAW, Volokhina EB, van den Heuvel LPWJ. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Front Immunol 2018;9:612. [PMID: 29670616 DOI: 10.3389/fimmu.2018.00612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
262 Chen P, Zhu L, Yu F, Han SS, Meng SJ, Guo WY, Zhang H, Song Y. Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report. Medicine (Baltimore) 2017;96:e7144. [PMID: 28614243 DOI: 10.1097/MD.0000000000007144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
263 Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. Front Immunol 2019;10:1030. [PMID: 31214159 DOI: 10.3389/fimmu.2019.01030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
264 Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ. Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol 2014;9:1876-82. [PMID: 25341722 DOI: 10.2215/CJN.01820214] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
265 Ali A, Schlanger L, Nasr SH, Sethi S, Gorbatkin SM. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure. Am J Kidney Dis 2016;67:479-82. [PMID: 26704376 DOI: 10.1053/j.ajkd.2015.10.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
266 Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol 2018;13:406-13. [PMID: 29326307 DOI: 10.2215/CJN.09080817] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
267 Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J. Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Nefrologiâ (St -Peterbg ) 2021;25:96-119. [DOI: 10.36485/1561-6274-2021-25-1-96-119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
268 Bobart SA, Alexander MP, Bentall A. Recurrent Glomerulonephritis in the Kidney Allograft. Indian J Nephrol 2020;30:359-69. [PMID: 33840954 DOI: 10.4103/ijn.IJN_193_19] [Reference Citation Analysis]
269 Gnappi E, Allinovi M, Vaglio A, Bresin E, Sorosina A, Pilato FP, Allegri L, Manenti L. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012;27:1995-9. [DOI: 10.1007/s00467-012-2210-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
270 Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-durey M, Frémeaux-bacchi V. Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS). In: Gadjeva M, editor. The Complement System. Totowa: Humana Press; 2014. pp. 237-47. [DOI: 10.1007/978-1-62703-724-2_19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
271 Sethi S, De Vriese AS, Fervenza FC. Acute glomerulonephritis. The Lancet 2022;399:1646-63. [DOI: 10.1016/s0140-6736(22)00461-5] [Reference Citation Analysis]
272 Chauvet S, Servais A, Frémeaux-Bacchi V. [C3 glomerulopathy]. Nephrol Ther 2014;10:78-85. [PMID: 24508002 DOI: 10.1016/j.nephro.2013.09.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Cavanaugh C, Okusa MD. The Evolving Role of Novel Biomarkers in Glomerular Disease: A Review. American Journal of Kidney Diseases 2021;77:122-31. [DOI: 10.1053/j.ajkd.2020.06.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
274 Hamzi MA, Zniber A, Badaoui GE, Mahtat E, Alhamany Z, Bayahia R, Ouzeddoun N. C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. Indian J Nephrol 2017;27:141-4. [PMID: 28356669 DOI: 10.4103/0971-4065.181884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
275 Heeringa SF, Cohen CD. Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol. 2012;2012:695131. [PMID: 23227086 DOI: 10.1155/2012/695131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
276 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
277 Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol. 2014;27:457-460. [PMID: 24536001 DOI: 10.1007/s40620-013-0008-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
278 Larsen CP, Walker PD. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far. Kidney Int 2013;83:331-2. [PMID: 23364589 DOI: 10.1038/ki.2012.385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
279 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
280 Nichols EM, Barbour TD, Pappworth IY, Wong EK, Palmer JM, Sheerin NS, Pickering MC, Marchbank KJ. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int 2015;88:1314-22. [PMID: 26221753 DOI: 10.1038/ki.2015.233] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
281 D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? Kidney Int 2012;82:379-81. [PMID: 22846813 DOI: 10.1038/ki.2012.80] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
282 Chanchlani R, Thorner P, Radhakrishnan S, Hebert D, Langlois V, Arora S, Barth D, Cattran D, Kirschfink M, Licht C. Long-term Eculizumab Therapy in a Child With Refractory Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Kidney Int Rep 2018;3:482-5. [PMID: 29725653 DOI: 10.1016/j.ekir.2017.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
283 Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, Carss K, Christian MT, Hall M, Harris CL, McAlinden P, Marchbank KJ, Marks SD, Maxwell H, Megy K, Penkett CJ, Mozere M, Stirrups KE, Tuna S, Wessels J, Whitehorn D, Johnson SA, Gale DP; MPGN/DDD/C3 Glomerulopathy Rare Disease Group., NIHR BioResource. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:365-73. [PMID: 31919107 DOI: 10.1681/ASN.2019040433] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
284 Cara-Fuentes G, Smoyer WE. Biomarkers in pediatric glomerulonephritis and nephrotic syndrome. Pediatr Nephrol 2021;36:2659-73. [PMID: 33389089 DOI: 10.1007/s00467-020-04867-y] [Reference Citation Analysis]
285 Mathur M, Sharma S, Prasad D, Garsa R, Singh AP, Kumar R, Beniwal P, Agarwal D, Malhotra V. Incidence and profile of C3 Glomerulopathy: A single center study. Indian J Nephrol 2015;25:8-11. [PMID: 25684865 DOI: 10.4103/0971-4065.136889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
286 Silva F, Tavares J, Peixeiro RP, Oliveira J, Fernandes D, Castro A, Santos S, Coutinho R, Freitas C, Santos J, Pimentel JP, Coutinho J, Cabrita A. C3 glomerulopathy associated to B-cell chronic lymphocytic leukemia. Nefrologia (Engl Ed) 2020:S0211-6995(20)30173-9. [PMID: 33358218 DOI: 10.1016/j.nefro.2020.08.010] [Reference Citation Analysis]
287 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
288 Figuères ML, Frémeaux-Bacchi V, Rabant M, Galmiche L, Marinozzi MC, Grünfeld JP, Noël LH, Servais A. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. Hum Pathol 2014;45:2326-33. [PMID: 25260719 DOI: 10.1016/j.humpath.2014.07.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
289 Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One 2013;8:e70269. [PMID: 23894628 DOI: 10.1371/journal.pone.0070269] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
290 Mansour-Hendili L, Aissat A, Badaoui B, Sakka M, Gameiro C, Ortonne V, Wagner-Ballon O, Pissard S, Picard V, Ghazal K, Bahuau M, Guitton C, Mansour Z, Duplan M, Petit A, Costedoat-Chalumeau N, Michel M, Bartolucci P, Moutereau S, Funalot B, Galactéros F. Exome sequencing for diagnosis of congenital hemolytic anemia. Orphanet J Rare Dis 2020;15:180. [PMID: 32641076 DOI: 10.1186/s13023-020-01425-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
291 Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-bacchi V, Sellier-leclerc AL. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 2017;32:1023-8. [DOI: 10.1007/s00467-017-3619-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
292 Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85:450-6. [PMID: 24067430 DOI: 10.1038/ki.2013.340] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 11.9] [Reference Citation Analysis]
293 Piras R, Breno M, Valoti E, Alberti M, Iatropoulos P, Mele C, Bresin E, Donadelli R, Cuccarolo P, Smith RJH, Benigni A, Remuzzi G, Noris M. CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Genet 2021;12:670727. [PMID: 34211499 DOI: 10.3389/fgene.2021.670727] [Reference Citation Analysis]
294 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
295 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
296 Cserhalmi M, Uzonyi B, Merle NS, Csuka D, Meusburger E, Lhotta K, Prohászka Z, Józsi M. Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. Front Immunol 2017;8:1800. [PMID: 29321782 DOI: 10.3389/fimmu.2017.01800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
297 Yurova VA, Bobrova LA, Kozlovskaya NL, Korotchaeva YV, Serova AG, Kozlov LV, Andina SS, Demyanova KA, Kuchieva AM, Roshchupkina SV. [Changes in the complement system in membranoproliferative glomerulonephritis]. Ter Arkh 2017;89:69-77. [PMID: 28745692 DOI: 10.17116/terarkh201789669-77] [Reference Citation Analysis]
298 Medjeral-Thomas NR, Moffitt H, Lomax-Browne HJ, Constantinou N, Cairns T, Cook HT, Pickering MC. Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. Kidney Int Rep 2019;4:1387-400. [PMID: 31701048 DOI: 10.1016/j.ekir.2019.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
299 Berthe-Aucejo A, Sacquépée M, Fila M, Peuchmaur M, Perrier-Cornet E, Frémeaux-Bacchi V, Deschênes G. Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol 2014;2014:201568. [PMID: 24672732 DOI: 10.1155/2014/201568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
300 Bomback AS, Markowitz GS, Appel GB. Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney Int Rep 2016;1:148-55. [PMID: 29142924 DOI: 10.1016/j.ekir.2016.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
301 Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014;9:600-608. [PMID: 24408117 DOI: 10.2215/cjn.06410613] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
302 Cook HT. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. Curr Opin Nephrol Hypertens 2018;27:165-70. [PMID: 29517501 DOI: 10.1097/MNH.0000000000000412] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
303 Frangou E, Varnavidou-Nicolaidou A, Petousis P, Soloukides A, Theophanous E, Savva I, Michael N, Toumasi E, Georgiou D, Stylianou G, Mean R, Anastasiadou N, Athanasiou Y, Zavros M, Kyriacou K, Deltas C, Hadjianastassiou V. Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy. Nephrol Dial Transplant 2019;34:1780-8. [PMID: 30844074 DOI: 10.1093/ndt/gfz021] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Lim WH, Shingde M, Wong G. Recurrent and de novo Glomerulonephritis After Kidney Transplantation. Front Immunol 2019;10:1944. [PMID: 31475005 DOI: 10.3389/fimmu.2019.01944] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
305 Pinho A, Ferreira G, Mota C. Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report. BMC Res Notes 2014;7:792. [PMID: 25380644 DOI: 10.1186/1756-0500-7-792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
306 Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 2016;95:e4104. [PMID: 27399110 DOI: 10.1097/MD.0000000000004104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Córdoba SR, Noris M. The role of complement in C3 glomerulopathy. Mol Immunol. 2015;67:21-30. [PMID: 25929733 DOI: 10.1016/j.molimm.2015.03.012] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
308 Mack HG, Colville DJ, Harraka P, Savige JA, Invernizzi A, Fraser-Bell S. Retinal findings in glomerulonephritis. Clin Exp Optom 2021;:1-13. [PMID: 34877922 DOI: 10.1080/08164622.2021.2003691] [Reference Citation Analysis]